Prelude Therapeutics Inc (PRLD)

Apr 25, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting | PR - GuruFocus

Apr 25, 2025

Apr 25, 2025

Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting - Nasdaq

Apr 25, 2025

Apr 25, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting - Yahoo Finance

Apr 25, 2025

Apr 11, 2025

HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World

Apr 11, 2025

Apr 10, 2025

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN

Apr 10, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Apr 02, 2025

Apr 02, 2025

Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo

Apr 02, 2025

Apr 01, 2025

Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech

Apr 01, 2025

Mar 29, 2025

Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo

Mar 29, 2025

Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025

Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025

Mar 28, 2025

Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com India

Mar 28, 2025

Mar 27, 2025

Prelude Therapeutics stock surges on insider buying - Investing.com

Mar 27, 2025

Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com Australia

Mar 27, 2025

Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com

Mar 27, 2025

Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 26, 2025

PRLD stock touches 52-week low at $0.66 amid sharp annual decline - Investing.com

Mar 26, 2025

Mar 25, 2025

Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com

Mar 25, 2025

Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia

Mar 24, 2025

Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India

Mar 24, 2025

Mar 22, 2025

Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MyChesCo

Mar 22, 2025

Mar 19, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 17, 2025

Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia

Mar 17, 2025

Mar 16, 2025

NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo

Mar 16, 2025

Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025

Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa

Mar 14, 2025

Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com

Mar 14, 2025

Mar 13, 2025

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo

Mar 13, 2025

Mar 12, 2025

Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD) - The Globe and Mail

Mar 12, 2025

Mar 11, 2025

Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Mar 11, 2025

Mar 11, 2025

Rhumbline Advisers Increases Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - The AM Reporter

Mar 11, 2025

Mar 11, 2025

Prelude Therapeutics Reports 2024 Financial Results - TipRanks

Mar 11, 2025

Mar 10, 2025

Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025

Mar 10, 2025

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks

Mar 10, 2025

Mar 10, 2025

Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 10, 2025

Mar 10, 2025

Prelude Therapeutics Inc SEC 10-K Report - TradingView

Mar 10, 2025

Mar 10, 2025

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire

Mar 10, 2025

Mar 10, 2025

PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 10, 2025

Mar 09, 2025

Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo

Mar 09, 2025

Mar 07, 2025

Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo

Mar 07, 2025

Mar 06, 2025

Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN

Mar 06, 2025

Mar 05, 2025

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo

Mar 05, 2025

Mar 05, 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire

Mar 05, 2025

Mar 05, 2025

How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan

Mar 05, 2025

Mar 05, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo

Mar 05, 2025

Mar 04, 2025

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance

Mar 04, 2025